Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co. Buys Out OncoImmune For Phase III COVID-19 Therapy

Executive Summary

Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.

You may also be interested in...



Merck’s COVID-19 Therapeutic Development Path Gets A Little Harder

After backing off of MRK-7110 for hospitalized patients the company’s focus is on the oral antiviral molnupiravir for outpatients – which would be a huge win, but the drug has yet to fully prove itself in the clinic.

Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint

The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.

Coronavirus Update: Regeneron's New Antibody Efficacy; Pfizer And Merck Strike US Contracts

Regeneron's antibody cocktail prevented deaths and mechanical ventilation in hospitalized patients on low-flow oxygen. Also, Pfizer and BioNTech will supply an additional 100m doses of the companies' COVID-19 vaccine to the US government for $1.95bn, while Merck & Co signed a contract for its COVID-19 treatment MK-7110. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel